The world health organization has predicted high mortality rates due to infection by drug-resistant pathogens and has called for taking urgent measures to mitigate the crisis (WHO Report , 2019). While several national and international bodies have taken initiatives for finding new antibiotics, a less enthusiastic R&D by pharmaceutical companies towards antimicrobial drug discovery has aggravated the crisis globally. The alarming rate of occurrence of multidrug-resistant (MDR-TB) and extensively drug-resistant t uberculosis (XDR-TB) therefore mandates pacing up the efforts to discover new drugs as well as explore alternative options with open mind.
